pdufa.bio
Home › Condition › Obesity & Metabolic

Upcoming Obesity & Metabolic FDA decisions & readouts

Page updated ·next FDA decision on the calendar ·Data as of Nov 5, 2026 9:00 PM ET
PDUFA target dates and trial readouts in obesity & metabolic, each linked to its primary source. Updated from FDA/SEC/ClinicalTrials.gov; dates can shift.
Cancer & OncologyCNS & NeurologyImmunology & InflammationCardiovascularRare DiseaseInfectious Disease & VaccinesHematologyOphthalmology & Eye

PDUFA decisions (2)

CORT · 2026-12-17
Relacorilant - (GRACE resubmission): Cushing's syndrome (hypercortisolism)
NVO · Dec 2026 (est.)
CagriSema (AM833): Obesity / weight management

Trial readouts (5)

MNOV · Dec 2026 (est.)
MN-166
IVEVF · 2026-12-31
lanifibranor NATiV3 Phase 3: non-cirrhotic MASH (F2/F3)
VKTX · Jul 2027 (est.)
VK2735
LLY · Oct 2027 (est.)
Tirzepatide
GPCR · 2027-12-31
ACCG-2671 Phase 1/2a MAD portion (12-week, obesity): obesity

Every upcoming FDA decision date, all therapeutic areas, on the 2026 PDUFA calendar · all conditions

We don't show an approval percentage for these obesity & metabolic catalysts: here's why.